查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球艰难梭菌感染治疗市场：按药物类型（万古霉素、甲硝唑、非达霉素等）、给药途径、分销渠道、地区 - 规模、份额、前景、机会分析，2023-2030 年
市场调查报告书
商品编码
1233307

全球艰难梭菌感染治疗市场：按药物类型（万古霉素、甲硝唑、非达霉素等）、给药途径、分销渠道、地区 - 规模、份额、前景、机会分析，2023-2030 年

Clostridioides Difficile Infection Treatment Market, by Drug Type (Vancomycin, Metronidazole, Fidaxomicin, and Others ), by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 182 Pages | 商品交期: 2-3个工作天内

价格
简介目录

艰难梭菌可产生革兰氏阳性菌，是一种厌氧毒素，通过粪口途径传播。 艰难梭菌感染的严重感染可导致水样腹泻、腹部绞痛、剧烈疼痛、脱水、心跳加快、白细胞计数升高、噁心和肾功能衰竭。 艰难梭菌感染可在抗生素治疗期间发生或由医疗保健相关感染引起，临床表现从无症状感染到水样腹泻、结肠炎和结肠穿孔等严重并发症不等。 只有少数药物如甲硝唑、非多霉素和万古霉素可用于治疗艰难梭菌感染。 如果有严重的腹壁疼痛或中毒性巨结肠，患者会接受手术切除感染区域。 这种疾病的高患病率和新兴国家偶尔爆发的疾病预计将推动艰难梭菌感染治疗市场的增长。 然而，头孢菌素类和氟奎诺酮类等广谱抗生素替代疗法将阻碍艰难梭菌感染治疗市场的增长。

市场动态

在预测期内，一些政府和非政府组织开展的提高认识活动预计将在推动全球艰难梭菌感染治疗市场的增长方面发挥关键作用。 例如，2020 年 12 月，由非营利性全国性艰难梭菌宣传组织 Peggy Lillis Foundation 发起，覆盖超过 250,000 名美国人以传播对艰难梭菌的认识。宣布其目标已实现。 2019 年，该组织发起了“See C.diff”以纪念艰难梭菌（Clostridium difficile）宣传活动，并惠及了约 80,000 人。

此外，在 2021 年 3 月，Peggy Lilith Foundation 是一家在全国范围内开展艰难梭菌意识提升活动的非营利性公司，将由 Ferring 製药公司支持艰难梭菌感染患者。□与 Pharmaceuticals 合作. Peggy Lilith Foundation 和 Ferring Pharmaceuticals 之间的合作伙伴关係通过新的讚助来帮助患有艰难梭菌感染的患者，以资助新的和现有的患者宣传工作。

此外，2021 年 12 月 4 日，Peggy Lillis 基金会宣布其在美国开展的艰难梭菌宣传活动已惠及超过 100 万人。

这项研究的主要特点

  • 本报告对全球艰难梭菌传染病市场进行了深入分析，结合以 2022 年为基准年的预测期（2023-2030 年）的市场规模为 8.934 亿美元。显示年增长率 (复合年增长率 7.1%)。
  • 它还阐明了各个细分市场的潜在创收机会，并描述了该市场具有吸引力的投资建议矩阵。
  • 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
  • 本文根据以下参数介绍了全球艰难梭菌感染市场的主要参与者——公司亮点、产品组合、主要亮点、财务业绩、本研究的策略主要公司包括 Novartis AG、Baxter、ANI Pharmaceuticals, Inc.、Mylan N.V.、Akorn、Sun Pharmaceutical Industries Ltd.、Merck & Co., Inc.、B. Braun Medical Inc.、Teva Pharmaceutical Industries Ltd.、Hikma Pharmaceutical PLC、Perrigo Pharmaceutical.、Apotex Inc.、AbbVie Inc.、Ferring Pharmaceuticals、Fresenius Kabi USA.、Pfizer Inc.、Strides Pharma Science Limited.、Sanofi.、AstraZeneca.、Eli Lilly and Company.、Actelion Pharmaceuticals Ltd. 和 Astellas Pharma
  • 这份报告中的见解将帮助营销人员和企业高管就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 《全球艰难梭菌传染病市场报告》面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以通过用于分析全球艰难梭菌感染市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写

第二章市场范围

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 按药物类型划分的市场概况
    • 按给药途径划分的市场概况
    • 市场概况：按分销渠道
    • 市场概况：按地区
  • 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

  • 市场动态
    • 司机
    • 约束因素
    • 市场吸引力分析
    • 市场机会
  • 产品发布
  • 合併/收购/联合研究
  • 监管准则和合规性
  • 主要发展
  • 政府举措
  • 害虫分析
  • 技术概况
  • 对 PORTER 的分析
  • 价格分析

第 4 章艰难梭菌感染药物的全球市场 - 冠状病毒 (COVID-19) 大流行的影响

  • 经济影响
  • COVID-19 流行病学
  • 对供需的影响

第 5 章：按药物类型分列的艰难梭菌感染全球药物市场：2017-2030

  • 万古霉素
  • 甲硝唑
  • 非达霉素
  • 其他（仿製药等）

第 6 章：按给药途径分列的全球艰难梭菌药物市场，2017-2030

  • 口语
  • 可注射

第 7 章。全球艰难梭菌药物市场：按分销渠道，2017-2030

  • 医院药房
  • 零售药房
  • 在线药店

第 8 章。全球艰难梭菌药物市场：按地区划分，2017-2030

  • 北美
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地区
  • 欧洲
  • 英国
  • 德国
  • 意大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 东盟
  • 澳大利亚
  • 韩国
  • 其他亚太地区
  • 中东
  • 海湾合作委员会
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中非
  • 南非

第9章竞争格局

  • Novartis AG
  • Baxter
  • ANI Pharmaceuticals, Inc.
  • Mylan N.V.
  • Akorn
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Braun Medical Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceutical PLC
  • Perrigo Pharmaceutical
  • Apotex Inc.
  • AbbVie Inc.
  • Ferring Pharmaceuticals
  • Fresenius Kabi USA.
  • Pfizer Inc.
  • Strides Pharma Science Limited
  • Sanofi
  • AstraZeneca
  • Eli Lilly and Company
  • Actelion Pharmaceuticals Ltd.
  • Astellas Pharma

第 10 章

  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI1492

Clostridiodes Difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through the fecal-oral route. The severe infection of clostridium difficile infection is watery diarrhea, abdominal cramping, and pain, which may be severe, dehydration, rapid heart rate, increased white blood cell count, nausea, and kidney failure. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare-associated infection with clinical manifestations ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. Limited types of drugs such as metronidazole, fidoxamicin, and vancomycin are only available for the treatment of Clostridium difficile infection. In case of any severe pain or toxic megacolon in the abdominal wall, patients undergo surgery for the removal of the infected portion. The high prevalence of this disease and occasional disease outbreaks in emerging economies is expected to drive the growth of clostridioides difficile infection treatment market. However, alternative therapy for a broad-spectrum antibiotic such as cephalosporins or fluoroquinolone will hinder the growth of Clostridioides difficile Infection treatment market .

Market Dynamics

Increasing awareness campaigns by several government and non-government organizations are expected to play important role in driving the growth of the global clostridioides difficile infection treatment market growth for the forecast period. For instance, in December 2020, launched by Peggy Lillis Foundation, a nationwide Clostridium difficile awareness organizer, a not-for-profit corporation, announced that they have acomplished their objective by reaching more than 250,000 Americans to spread awareness regarding Clostridium Difficile. The organization launched the 'See C. diff' to commemorate C. diff (Clostridium Difficile) awareness campaign in 2019, and reached about 80,000 people.

Furthermore, in March 2021, Peggy Lillis Foundation, a nationwide Clostridium difficile awareness organizer and a not-for-profit corporation, partnered with Ferring Pharmaceuticals, pharmaceutical company, to help and support patients with clostridioides difficile infection. The partnership between Peggy Lillis Foundation and Ferring Pharmaceuticals helped patients suffering from clostridioides difficile infection through new sponsorship to fund new and existing patient advocacy initiatives.

Moreover, on December 4, 2021, the Peggy Lillis Foundation, announced that they have reached more than 1 million people during C. diff awareness campaign in U. S.

Key features of the study:

  • This report provides in-depth analysis of the global clostridioides difficile infection market, and provides market size (US$ 893.4 Million) and compound annual growth rate (CAGR 7.1 %) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global clostridioides difficile infection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Novartis AG, Baxter, ANI Pharmaceuticals, Inc., Mylan N.V., Akorn, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., B. Braun Medical Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceutical PLC, Perrigo Pharmaceutical., Apotex Inc., AbbVie Inc., Ferring Pharmaceuticals, Fresenius Kabi USA., Pfizer Inc., Strides Pharma Science Limited., Sanofi., AstraZeneca., Eli Lilly and Company., Actelion Pharmaceuticals Ltd., and Astellas Pharma
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global clostridioides difficile infection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global clostridioides difficile infection market

Detailed Segmentation:

  • Global Clostridioides Difficile Infection Treatment Market, By Drug Type:
    • Vancomycin
    • Metronidazole
    • Fidaxomicin
    • Others (late phase drugs, etc.)
  • Global Clostridioides Difficile Infection Treatment Market, By Route of Administration:
    • Oral
    • Injectable
  • Global Clostridioides Difficile Infection Treatment Market By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Clostridioides Difficile Infection Treatment Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Novartis AG*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Baxter
    • ANI Pharmaceuticals, Inc.
    • Mylan N.V.
    • Akorn
    • Sun Pharmaceutical Industries Ltd.
    • Merck & Co., Inc.
    • B.Braun Medical Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Hikma Pharmaceutical PLC
    • Perrigo Pharmaceutical
    • Apotex Inc.
    • AbbVie Inc.,
    • Ferring Pharmaceuticals
    • Fresenius Kabi USA.
    • Pfizer Inc.,
    • Strides Pharma Science Limited.
    • Sanofi
    • AstraZeneca
    • Eli Lilly and Company
    • Actelion Pharmaceuticals Ltd.
    • Astellas Pharma

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Attractiveness Analysis
    • Market Opportunities
  • Product Launches
  • Merger, Acquisition, Collaborations
  • Regulatory Guideline and Compliances
  • Key Developments
  • Government Initiatives
  • PEST Analysis
  • Technology Landscape
  • PORTER's Analysis
  • Pricing Analysis

4. Global Clostridioides Difficile Infection Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Clostridioides Difficile Infection Treatment Market, By Drug Type, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Vancomycin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Metronidazole
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Fidaxomicin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others (late phase drugs, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Clostridioides Difficile Infection Treatment Market, By Route of Administration, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Clostridioides Difficile Infection Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segments Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Clostridioides Difficile Infection Treatment Market, By Region, 2017 - 2030, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Baxter
  • ANI Pharmaceuticals, Inc.
  • Mylan N.V.
  • Akorn
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Braun Medical Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceutical PLC
  • Perrigo Pharmaceutical
  • Apotex Inc.
  • AbbVie Inc.
  • Ferring Pharmaceuticals
  • Fresenius Kabi USA.
  • Pfizer Inc.
  • Strides Pharma Science Limited
  • Sanofi
  • AstraZeneca
  • Eli Lilly and Company
  • Actelion Pharmaceuticals Ltd.
  • Astellas Pharma

10. Section

  • Research Methodology
  • About Us